RNA-targeted oncology Skyhawk Therapeutics focuses on small molecules that modify RNA expression with first drug candidates targeting cancers, presenting a clear opportunity to pursue partnerships or licensing deals in oncology where RNA-splicing approaches may complement existing pipelines.

Neurology expansion Active collaborations and trials aimed at Huntington's disease and other neurological conditions indicate a continued market focus; sales teams should pursue co-development, regional expansion, or tolling arrangements with pharma companies seeking RNA-targeting neurology solutions.

Strategic partnerships Recent and ongoing partnerships with Merck KGaA and international collaborations (France) signal a receptiveness to external development and commercialization partnerships; target opportunities include strategic alliances, SAD/late-stage financing, or milestone-based collaborations.

Clinical progress signal Advancement of RNA-splicing candidates into pivotal development and upcoming site expansions in the US (HDSA Convention updates) suggest readiness for partner-led commercialization discussions, including regional manufacturing and supply chain alignment.

Commercial leadership Appointment of a Chief Commercial Officer to lead SKY-0515 indicates a formal go-to-market strategy; engage in conversations around market access, pricing, and payer strategies early to align with anticipated launch timelines.